, and its partner BioNTech, have started clinical trials for a new COVID-19 vaccine that is specifically targeted at the variant, which they say could be available as early as late March. The based pharmaceutical company announced Tuesday that it is recruiting 1,420 participants for a three cohort trial that will determine the safety and effectiveness of the company's shot.Albert Bourla, CEO of the company, indicated earlier this month that his company expects to submit data for authorization to the Food and Drug Administration () in March.
Load More
Load More